Introduction
============

As one of the leading malignant tumors worldwide, esophageal cancer (EC) is common in China with 477,900 new cases and 375,000 deaths [@B1]. Esophageal squamous cell carcinoma (ESCC) is the main pathological type of EC in China [@B2]. Although there are many therapies for patients with ESCC, the prognosis for patients with ESCC remains poor [@B3], [@B4]. Surgical resection remains the first choice for patients with early-stage disease, while chemoradiotherapy is the mainstay treatment in patients with local advanced disease. Therefore, it is very necessary to find more useful and effective preoperative clinical variables for patients with ESCC.

The nutrition and inflammation play an important role in cancer prognosis [@B5]. Some studies revealed that neutrophil to lymphocyte ratio (NLR) and C-reactive protein (CRP) were associated with prognosis in several types of cancers, including EC [@B6]-[@B9]. As an important nutritional factor, albumin (ALB) reflected the nutritional status in a variety of cancers. Some studies published in recent years revealed that ALB was still a controversial prognostic factor in patients with EC [@B10], [@B11]. It has been reported that lactate dehydrogenase (LDH) may act as an indicator for tumor burden and aggressiveness [@B12], [@B13]. Patients with high level of serum LDH have worse prognosis, but remains controversial in ESCC [@B14]-[@B16].

Recently, the Gustave Roussy Immune Score (GRIm-Score) was firstly identified with the purpose of a better patient selection in clinical trials for immunotherapy [@B17]. The results demonstrated that the GRIm-Score, based on NLR, LDH and ALB, is a better prognostic marker for patients enrolled in experimental trials. Moreover, the prognostic value of GRIm-Score has been confirmed in non-small cell lung cancer [@B18], [@B19]. However, as far as we know, there are no studies regarding the prognostic value of GRIm-Score in patients with ESCC so far. The purpose of the current study was to evaluate the prognostic value of GRIm-Score in patients with resectable ESCC.

Materials and Methods
=====================

Patients
--------

We retrospectively analyzed the clinical characteristics of 372 resectable patients with ESCC who undergoing curative esophagectomy between January 2006 and December 2010. This was a single institutional study. The inclusion criteria were as follow: (1) ESCC with stage I-III was confirmed by histopathology, (2) curative esophagectomy was performed without any neoadjuvant chemoradiotherapy, and (3) clinical characteristics and preoperative laboratory results, such as neutrophil, lymphocyte, LDH, ALB and CRP, were obtained before surgery within one week. The study was approved by the Ethics Committees, and written informed consent for the collection of specimen was obtained from each patient. The last follow up time was June 2014.

Data collection
---------------

The main clinical characteristics requiring analysis were collected from our medical records. The levels of neutrophil, lymphocyte, LDH, ALB and CRP were obtained within one week before surgery. The 7th AJCC/UICC TNM staging system was used in the current study [@B20]. The GRIm-Score is calculated by the following three variables: LDH (within normal range: 0 vs. \> upper limit of normal (ULN) of each center, 240 U/L in our hospital: +1), ALB (≥ 35 g/L: 0 vs. \< 35g/L: +1), and NLR (≤ 6: 0 vs. \> 6: +1). Patients were divided into two groups: high group (score 2 or 3) and low group (score 0 or 1) [@B17].

Statistical analyses
--------------------

The Chi-squared test (for categorical variables), Student\'s t-test (for continuous variables with Gaussian distribution) and Mann-Whitney U test (for continuous variables without Gaussian distribution) were performed to compare the clinical characteristics grouped by GRIm-Score. The endpoint for the current study was cancer-specific survival (CSS). The Kaplan-Meier method was used to compare the CSS by using the log-rank test. Multivariate analyses with Cox regression analyses by forward stepwise regression were used to evaluate the independent prognostic factors. The areas under the curve (AUC) for NLR, LDH, ALB, CRP and GRIm-Score were compared and calculated with the receiver operating characteristic (ROC) curves. A nomogram model with R 3.6.0 software was used to predict the 1-, 3- and 5-year CSS probability by using the independent prognostic factors in multivariate analyses [@B21]. All statistical analyses were performed with MedCalc 15.2 (MedCalc Software bvba, Ostend, Belgium) and SPSS 20.0 (SPSS Inc., Chicago, IL, USA).

Results
=======

Patient Characteristics
-----------------------

There were 284 (76.3%) men and 88 (23.7%) women with the mean age of 59.3 ± 8.0 years (range: 36-80 years). According to clinical criteria, a total of 115 patients (30.9%) received postoperative adjuvant radiotherapy and/or chemotherapy. The histograms of the NLR, LDH and ALB were shown in Figure [1](#F1){ref-type="fig"}. There were negative correlations between NLR and ALB (r = -0.169, *P* = 0.001; Fig. [2](#F2){ref-type="fig"}A), positive correlations between NLR and LDH (r = 0.174, *P* = 0.001; Fig. [2](#F2){ref-type="fig"}B), but no correlations between ALB and LDH (r = -0.078, *P* = 0.135; Fig. [2](#F2){ref-type="fig"}C). The clinical characteristics regarding GRIm-Score were shown in Table [1](#T1){ref-type="table"}.

CSS analyses
------------

At the last follow-up time, 256 (68.8%) of the 372 patients had died. Patients with a high GRIm-Score had poor 5-year CSS (10.3% vs. 35.0%, *P* \< 0.001) (Fig. [3](#F3){ref-type="fig"}A). In subgroup analyses based on TNM stage (TNM I, TNM II and TNM III), we revealed that GRIm-Score was also significantly related to CSS in TNM II (*P* = 0.020) and TNM III (*P* = 0.011), but not in TNM I (*P* = 0.334) (Fig. [3](#F3){ref-type="fig"}B-D). The significantly differences for 5-year CSS were also found in NLR (34.4% vs. 10.2%, *P* \< 0.001), ALB (35.0% vs. 15.3%, *P* \< 0.001), LDH (35.8% vs. 16.7%, *P* \< 0.001) and CRP (36.7% vs. 15.5%, *P* \< 0.001) (Fig. [3](#F3){ref-type="fig"}E-H).

Cox regression analyses
-----------------------

Univariate analyses indicated that several clinical indexes, such as vessel invasion, perineural invasion, tumor length, TNM stage, CRP, ALB, NLR, LDH and GRIm-Score, were significant predictors of CSS (Table [2](#T2){ref-type="table"}). Multivariate analyses demonstrated that GRIm-Score (HR: 1.593, 95% CI: 1.156-2.197, *P* = 0.004), instead of NLR, LDH or ALB, was an independent prognostic factor (Table [3](#T3){ref-type="table"}). Furthermore, CRP (HR: 1.760, 95% CI: 1.339-2.314, *P* \< 0.001) and TNM stage (HR: 1.478, 95% CI: 1.027-2.129, *P* = 0.036 and HR: 2.364, 95% CI: 1.676-3.332, *P* \< 0.001) were other significant prognostic factors (Table [3](#T3){ref-type="table"}).

ROC curve analyses
------------------

The AUC areas were 0.644, 0.596, 0.564, 0.572 and 0.582 for GRIm-Score (95% CI: 0.593-0.693), CRP (95% CI: 0.544-0.646), NLR (95% CI: 0.512-0.615), ALB (95% CI: 0.520-0.623) and LDH (95% CI: 0.530-0.632), respectively (Fig. [4](#F4){ref-type="fig"}). Comparison of AUC areas regarding the GRIm-Score, CRP, NLR, ALB and LDH in ESCC were shown in Table [4](#T4){ref-type="table"}.

ROC curve analyses
------------------

The AUC areas were 0.644, 0.596, 0.564, 0.572 and 0.582 for GRIm-Score (95% CI: 0.593-0.693), CRP (95% CI: 0.544-0.646), NLR (95% CI: 0.512-0.615), ALB (95% CI: 0.520-0.623) and LDH (95% CI: 0.530-0.632), respectively (Fig. [4](#F4){ref-type="fig"}). Comparison of AUC areas regarding the GRIm-Score, CRP, NLR, ALB and LDH in ESCC were shown in Table [4](#T4){ref-type="table"}.

Nomogram analyses
-----------------

Moreover, a nomogram model, including the significant prognostic factors (GRIm-Score, TNM and CRP), was conducted to predict the 1-, 3- and 5-year CSS probability for patients with ESCC (Fig. [5](#F5){ref-type="fig"}). Two nomogram models were conducted for different GRIm-Score (GRIm-Score 0, 1 and GRIm-Score 0, 1, 2 and 3).

Discussion
==========

This study, as far as we know, is the first study in patients with ESCC to indicate the prognostic value of GRIm-Score. The current study revealed several important findings: (1) GRIm-Score was a strong prognostic marker for CSS; (2) GRIm-Score, instead of NLR, ALB or LDH, was a useful independent prognostic factor. Therefore, we concluded that the GRIm-score was not only a selective biomarkers for patients enrolled in clinical trials for immunotherapy, but also a useful prognostic biomarkers for ESCC patients undergoing surgical resection.

The GRIm-Score was firstly identified with the purpose of a better patient selection in clinical trials for immunotherapy [@B17]. The results demonstrated that the GRIm-Score, based on NLR, LDH and ALB, is a better prognostic marker for patients enrolled in experimental trials. Moreover, the prognostic value of GRIm-Score has been confirmed in non-small cell lung cancer in recent years [@B18], [@B19]. However, as far as we know, there are no studies regarding the prognostic value of GRIm-Score in ESCC patients so far. In our study, patients with a high GRIm-Score had worse 5-year CSS (10.3% vs. 35.0%, *P* \< 0.001). Multivariate analyses demonstrated that GRIm-Score (HR: 1.593, 95% CI: 1.156-2.197, *P* = 0.004), instead of NLR, LDH or ALB, was an independent prognostic factor.

The NLR, ALB and LDH are routine laboratory indicators in daily clinical practice. Recent studies reported that inflammation is associated with poor prognosis in cancers, with NLR as a sensitive inflammatory biomarker in several types of cancers, including EC [@B6]-[@B9]. The levels of ALB, as an important nutritional factor, reflected the nutritional status in a variety of cancers. Some studies published in recent years revealed that ALB was still a controversial prognostic factor in patients with EC [@B10], [@B11]. Patients with high level of serum LDH have worse prognosis, but remains controversial in ESCC [@B14]-[@B16]. A retrospective study including 906 patients with ESCC concluded that LDH was associated with overall survival (OS) with the optimal cutoff point of 361.5 U/L [@B14]. However, a total of 212 patients with ESCC undergoing chemoradiotherapy revealed that LDH (cutoff point: 170 U/L) was not associated with OS or progression-free survival (PFS) [@B15]. The results were consistent with another study including 447 patients with ESCC which revealed that LDH (cutoff point: 154.4 U/L) was not a prognostic factor regarding OS [@B16].

It should be noted that NLR, ALB and LDH, routine laboratory indicators in daily clinical practice, may be influenced by various conditions. In the present study, although NLR, ALB and LDH were found to be predictive factors for CSS in univariate analyses, multivariate analyses did not show these biomarkers to be independent prognostic factors. Therefore, GRIm-Score is a combined indicator which can reflect a mixed prognostic value.

It should be also noted that our results have potential clinical significance in the treatment of patients with ESCC. Patients in a high level of GRIm-Score with early-stage ESCC may require more frequent follow-up, while those with local advanced ESCC may need more adjuvant therapy. However, the results of our study should be validated in more large-sample prospective trials in future.

Some potential limitations of the current study should be mentioned. Firstly, the potential selection bias should be acknowledged due to the current study was a retrospective research with single center. Secondly, patients with preoperative treatment in the current study were excluded, which might have influenced the results for patients with ESCC who underwent surgical resection. As everyone knows, preoperative neoadjuvant therapy will have side effects on laboratory indicators. However, preoperative neoadjuvant therapy (chemotherapy and/or radiotherapy) followed by surgery improves survival in several randomized control trials for locally advanced disease of EC, but not for early-stage EC [@B22], [@B23]. Thirdly, due to lack of prospective study, the results of our study should be validated in more large-sample clinical trials in future. In the current study, a nomogram model, including the significant prognostic factors (GRIm-Score, TNM and CRP), was conducted to predict the 1-, 3- and 5-year CSS probability for patients with ESCC. However, we must acknowledge that our prognostic nomogram model was only developed, but not validated in this study. Therefore, the results of our study should be validated in future.

In summary, the GRIm-Score, a novel nutritional and inflammatory-based prognostic score, was an independent prognostic factor in patients with ESCC undergoing surgical resection. The current study, as far as we know, is the first study regarding the prognostic value of GRIm-Score in ESCC patients undergoing esophagectomy.

This study was funded by the Medical Health Science and Technology Project of Zhejiang Provincial Health Commission (NO. 2018KY290, 2019RC129 and 2019RC128).
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![**Correlations for NLR, LDH and ALB.** Negative correlations between NLR and ALB (A). Positive correlations between NLR and LDH (B). No correlations were found between ALB and LDH (C).](jcav11p1334g002){#F2}

![**CSS analyses.** Kaplan-Meier for CSS grouped by GRIm-Score (A). CSS analyses for GRIm-Score in subgroup analyses based on TNM stage (B-D). Kaplan-Meier for CSS grouped by NLR (E), LDH (F), ALB (G) and CRP (H).](jcav11p1334g003){#F3}

![**ROC analyses.** The AUC area of the GRIm-Score (0.644) was higher than that of CRP (0.596), NLR (0.564), ALB (0.572) and LDH (0.582) for all the ESCC patients.](jcav11p1334g004){#F4}

![**Nomogram analyses.** Two nomogram models were conducted for different GRIm-Score \[GRIm-Score 0, 1 (A) and GRIm-Score 0, 1, 2, 3 (B)\] to predict the 1-, 3- and 5-year CSS probability.](jcav11p1334g005){#F5}

###### 

Clinical characteristics based on GRIm-Score in patients with ESCC.

                            Total (n = 372)     Low (n = 314)      High (n = 58)       P-value
  ------------------------- ------------------- ------------------ ------------------- --------------
  Age (years)                                                                          
  Mean ± SD                 59.3 ± 8.0          59.5 ± 8.0         58.3 ± 7.7          0.322^\#^
  ≤ 60 / \> 60 (n)          210 / 162           176 / 138          34 / 24             0.717
  Gender (n)                                                                           
  Male / Female             284 / 88            238 / 76           46 / 12             0.563
  Tumor length (cm)                                                                    
  Median (IQR)              4.0 (3.0-5.3)       4.0 (3.0-5.0)      5.0 (4.0-6.3)       \< 0.001\*
  ≤ 3.0 / \> 3.0 (n)        106 / 266           97 / 217           9 / 49              0.017
  Tumor location (n)                                                                   
  Upper/ Middle/ Lower      25 / 172 / 175      22 / 142 / 150     3 / 30 / 25         0.632
  Vessel invasion (n)                                                                  
  Negative / Positive       312 / 60            264 / 50           48 / 10             0.802
  Perineural invasion (n)                                                              
  Negative / Positive       293 / 79            250 / 64           43 / 15             0.348
  Smoking (n)                                                                          
  No / Yes                  203 / 169           169 / 145          34 / 24             0.500
  Drinking (n)                                                                         
  No / Yes                  228 / 144           193 / 121          35 / 23             0.872
  Differentiation (n)                                                                  
  Well/ Moderate/ Poor      52 / 246 / 74       47 / 208 / 59      5 / 38 / 15         0.266
  TNM stage (n)                                                                        
  I / II / III              94 / 119 / 159      91 / 102 / 121     3 / 17 / 38         \< 0.001
  NLR                                                                                  
  Median (IQR)              2.93 (2.16-3.87)    2.74 (1.95-3.67)   6.32 (4.09-7.09)    \< 0.001^\*^
  ≤ 6 / \> 6 (n)            323 / 49            305 / 9            18 / 40             \< 0.001
  LDH (U/L)                                                                            
  Mean ± SD                 187.0 ± 66.1        177.2 ± 62.7       240.1 ± 58.7        \< 0.001^\#^
  ≤ 240 / \> 240 (n)        282 / 90            264 / 50           18 / 40             \< 0.001
  ALB (g/L)                                                                            
  Mean ± SD                 40.9 ± 5.5          41.7 ± 5.1         36.7 ± 5.6          \< 0.001^\#^
  \> 35 / ≤ 35 (n)          300 / 72            284 / 30           16 / 42             \< 0.001
  CRP (mg/L)                                                                           
  Median (IQR)              4.55 (1.96-10.26)   4.46 1.72-8.39)    7.52 (3.43-15.58)   \< 0.001^\*^
  ≤ 10 / \> 10 (n)          275 / 97            242 / 72           33 / 25             \< 0.001
  Adjuvant therapy                                                                     
  No / Yes                  257 / 115           220 / 94           37 / 21             0.342

ESCC: esophageal squamous cell carcinoma; GRIm-Score: Gustave Roussy Immune Score; CRP: C-reactive protein; ALB: albumin; LDH: lactate dehydrogenase; NLR: neutrophil to lymphocyte ratio; TNM: tumor node metastasis; SD: standard deviation; IQR: interquartile range. ^\#^: t-test; ^\*^: Mann-Whitney U test.

###### 

Univariate analyses of CSS in ESCC patients.

                        5-year CSS   Mediean (M)   P-value   HR (95% CI)           P-value
  --------------------- ------------ ------------- --------- --------------------- ---------
  Age (years)                                      0.997                           0.997
  ≤ 60                  30.5%        32                      1.000                 
  \> 60                 32.1%        32                      1.000 (0.780-1.280)   
  Gender                                           0.950                           0.951
  female                31.8%        28                      1.000                 
  male                  31.0%        32                      1.009 (0.756-1.348)   
  Tumor length (cm)                                0.003                           0.004
  ≤ 3.0                 39.6%        48                      1.000                 
  \> 3.0                27.8%        27                      1.522 (1.147-2.021)   
  Tumor location                                   0.381                           0.392
  upper                 44.0%        45                      1.000                 
  middle                29.1%        32                      1.471 (0.846-2.558)   0.172
  lower                 31.4%        32                      1.402 (0.806-2.439)   0.231
  Vessel invasion                                  0.015                           0.017
  negative              33.3%        36                      1.000                 
  positive              20.0%        20                      1.469 (1.073-2.013)   
  Perineural invasion                              0.006                           0.007
  negative              34.1%        39                      1.000                 
  positive              20.3%        20                      1.486 (1.117-1.977)   
  Smoking                                          0.265                           0.271
  no                    34.0%        35                      1.000                 
  yes                   27.8%        27                      1.148 (0.898-1.467)   
  Drinking                                         0.606                           0.610
  no                    30.3%        36                      1.000                 
  yes                   32.6%        25                      1.068 (0.830-1.375)   
  Differentiation                                  0.142                           0.150
  well                  38.5%        35                      1.000                 
  moderate              30.9%        34                      1.118 (0.766-1.631)   0.564
  poor                  27.0%        16                      1.461 (0.943-2.263)   0.089
  TNM stage                                        \<0.001                         \<0.001
  I                     48.9%        67                      1.000                 
  II                    33.6%        34                      1.697 (1.185-2.430)   0.004
  III                   18.9%        19                      2.784 (1.995-3.886)   \<0.001
  CRP (mg/L)                                       \<0.001                         \<0.001
  ≤ 10.0                36.7%        42                      1.000                 
  \> 10.0               15.5%        17                      2.060 (1.581-2.685)   
  ALB (g/L)                                        \<0.001                         \<0.001
  ≥ 35.0                35.0%        40                      1.000                 
  \< 35.0               15.3%        20                      1.979 (1.480-2.645)   
  NLR                                              \<0.001                         \<0.001
  ≤ 6.0                 34.4%        36                      1.000                 
  \> 6.0                10.2%        20                      2.029 (1.464-2.812)   
  LDH (U/L)                                        \<0.001                         \<0.001
  ≤ 240                 35.8%        39                      1.000                 
  \> 240                16.7%        20                      1.767 (1.348-2.315)   
  GRIm-Score                                       \<0.001                         \<0.001
  low                   35.0%        39                      1.000                 
  high                  10.3%        18                      2.246 (1.652-3.054)   
  Adjuvant therapy                                 0.129                           0.133
  No                    32.3%        38                      1.000                 
  Yes                   28.7%        23                      1.223 (0.940-1.591)   

ESCC: esophageal squamous cell carcinoma; CSS: cancer-specific survival; GRIm-Score: Gustave Roussy Immune Score; CRP: C-reactive protein; ALB: albumin; LDH: lactate dehydrogenase; TNM: tumor node metastasis; NLR: neutrophil to lymphocyte ratio; CI: confidence interval; HR: hazard ratio.

###### 

Multivariate analyses of CSS in patients with ESCC.

               HR (95% CI)           P-value
  ------------ --------------------- ---------
  TNM stage                          \<0.001
  I            1.000                 
  II           1.478 (1.027-2.129)   0.036
  III          2.364 (1.676-3.332)   \<0.001
  GRIm-Score                         0.004
  low          1.000                 
  high         1.593 (1.156-2.197)   
  CRP (mg/L)                         \<0.001
  ≤ 10.0       1.000                 
  \> 10.0      1.760 (1.339-2.314)   

ESCC: esophageal squamous cell carcinoma; CSS: cancer-specific survival; GRIm-Score: Gustave Roussy Immune Score; CRP: C-reactive protein; TNM: tumor node metastasis; CI: confidence interval; HR: hazard ratio.

###### 

Comparison of AUC areas for the prognostic factors in ESCC.

               AUC     95% CI        P-value
  ------------ ------- ------------- -----------
  GRIm-Score   0.644   0.593-0.693   Reference
  CRP          0.596   0.544-0.646   0.0897
  NLR          0.564   0.512-0.615   0.0001
  ALB          0.572   0.520-0.623   0.0001
  LDH          0.582   0.530-0.632   0.0004

ESCC: esophageal squamous cell carcinoma; GRIm-Score: Gustave Roussy Immune Score; CRP: C-reactive protein; ALB: albumin; LDH: lactate dehydrogenase; NLR: neutrophil to lymphocyte ratio; AUC: area under the curve.
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